Nycomed's PDE4 inhibitor Daxas has been licenced by Forest Labs for the US. This comes just a few weeks after Nycomed approached the US FDA for approval to market the COPD or Smoker's Lung drug. Forest will pay a $100mn upfront fee. Nycomed also stands to make an additional $5oomn based on regulatory approvals and commercial milestones from … Continue reading Waiting to exhale
Apothecurry 